Vanda Pharmaceuticals Inc. $VNDA Holdings Reduced by Jacobs Levy Equity Management Inc.

Key Points

• Jacobs Levy Equity Management Inc. has reduced its stake in Vanda Pharmaceuticals by 41.7%, selling 196,433 shares and now holding approximately 0.47% of the company.
• Vanda Pharmaceuticals reported a Q2 earnings loss of ($0.46) per share, missing the consensus estimate by ($0.12), with revenues below expectations at $52.59 million.
• Analysts have mixed views on Vanda Pharmaceuticals, with Wall Street Zen downgrading the stock to a "strong sell," while HC Wainwright maintains a "buy" rating with a price target of $20.00.

Jacobs Levy Equity Management Inc. lowered its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 41.7% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 274,293 shares of the biopharmaceutical company's stock after selling 196,433 shares during the period. Jacobs Levy Equity Management Inc. owned 0.47% of Vanda Pharmaceuticals worth $1,259,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of VNDA. Quantinno Capital Management LP bought a new stake in shares of Vanda Pharmaceuticals in the 4th quarter worth about $48,000. Linden Thomas Advisory Services LLC bought a new stake in shares of Vanda Pharmaceuticals in the 1st quarter worth about $49,000. Nations Financial Group Inc. IA ADV bought a new stake in shares of Vanda Pharmaceuticals in the 1st quarter worth about $67,000. Virtu Financial LLC bought a new stake in shares of Vanda Pharmaceuticals in the 1st quarter worth about $72,000. Finally, ProShare Advisors LLC increased its position in shares of Vanda Pharmaceuticals by 32.4% in the 4th quarter. ProShare Advisors LLC now owns 18,815 shares of the biopharmaceutical company's stock worth $90,000 after purchasing an additional 4,599 shares during the last quarter. Institutional investors own 88.14% of the company's stock.

Vanda Pharmaceuticals Trading Down 1.6%

VNDA traded down $0.07 on Wednesday, hitting $4.39. 291,184 shares of the company's stock were exchanged, compared to its average volume of 344,296. Vanda Pharmaceuticals Inc. has a twelve month low of $3.81 and a twelve month high of $5.55. The firm has a market cap of $259.40 million, a PE ratio of -3.88 and a beta of 0.74. The stock has a fifty day moving average of $4.57 and a two-hundred day moving average of $4.53.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.12). Vanda Pharmaceuticals had a negative return on equity of 12.89% and a negative net margin of 32.90%.The firm had revenue of $52.59 million during the quarter, compared to the consensus estimate of $54.77 million. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

Analyst Ratings Changes

VNDA has been the subject of several research analyst reports. Wall Street Zen downgraded shares of Vanda Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research report on Saturday, August 2nd. HC Wainwright reissued a "buy" rating and issued a $20.00 target price on shares of Vanda Pharmaceuticals in a research report on Thursday, August 21st. One research analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Strong Buy" and a consensus price target of $16.50.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.